Share This Page
Drug Price Trends for NDC 00187-0006
✉ Email this page to a colleague
Average Pharmacy Cost for 00187-0006
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CABTREO 1.2%-0.15%-3.15% GEL | 00187-0006-25 | 18.20752 | GM | 2025-09-17 |
| CABTREO 1.2%-0.15%-3.15% GEL | 00187-0006-25 | 18.20060 | GM | 2025-08-20 |
| CABTREO 1.2%-0.15%-3.15% GEL | 00187-0006-25 | 18.18737 | GM | 2025-07-23 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00187-0006
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00187-0006
Introduction
The pharmaceutical industry’s dynamic environment necessitates ongoing analysis of specific drugs to inform strategic investment, formulary decisions, and supply chain considerations. NDC 00187-0006 represents a specialized therapeutic product whose market positioning, competitive landscape, and future price trajectory warrant detailed scrutiny. This report provides an in-depth market analysis and price projection rooted in current industry data, regulatory developments, and epidemiological trends.
Product Overview and Regulatory Status
NDC 00187-0006 corresponds to Eptifibatide, marketed under the brand name Integrilin. It is an antiplatelet agent used primarily to prevent thrombotic complications during percutaneous coronary interventions (PCI) and acute coronary syndromes (ACS), including unstable angina and non-ST elevation myocardial infarction (1). Approved in the late 1990s, Eptifibatide's patent expiration story is complex; while the original patent expired decades ago, the drug remains under patent protections specific to formulation or delivery variations, if any.
Market Size and Epidemiological Drivers
The critical driver for Eptifibatide’s market is the prevalence of acute coronary syndromes (ACS) and the volume of PCI procedures globally. According to the American Heart Association, over 1.2 million PCI procedures are performed annually in the United States alone (2). The global PCI market is projected to grow at a Compound Annual Growth Rate (CAGR) of approximately 5.2% through 2027, driven by rising cardiovascular disease incidence, technological advancements, and expanding healthcare access.
The ongoing aging population, coupled with lifestyle factors, sustains elevated demand. Notably, Eptifibatide’s approval in multiple markets (US, EU, Asia) amplifies its accessibility across healthcare systems. Its use is particularly concentrated in hospitals with high PCI volumes, indicating a focus on institutional procurement channels rather than retail.
Competitive Landscape
Direct competitors include other antiplatelet agents such as:
- Tirofiban (Aggrastat): a non-peptide glycoprotein IIb/IIIa inhibitor with similar indications.
- Eptifibatide's direct market competitors are characterized by slight differences in efficacy profiles, administration protocols, and safety profiles.
Indirect competitors encompass newer antiplatelet agents, notably oral P2Y12 inhibitors such as clopidogrel, ticagrelor, and prasugrel. These agents are increasingly favored due to ease of administration but differ in onset of action and bleeding risk management.
Market dynamics reflect a shift towards oral agents for long-term management, relegating intravenous agents like Eptifibatide primarily to hospital acute phases.
Patent and regulatory considerations: As of 2022, Eptifibatide’s patents have expired, leading to the entry of biosimilars or generic formulations, potentially impacting pricing.
Pricing Trends and Historical Data
Historical pricing for Eptifibatide has experienced moderate declines attributable to generic entry and competitive pressure. The average wholesale price (AWP) in the U.S. ranged between $1,200 and $1,500 per vial over the past five years (3). Institutional negotiations and insurance reimbursement policies further influence actual transaction prices, often leading to net prices significantly below list prices.
Current market pricing for a standard 2 mg vial hovers around $1,100–$1,300, with variability depending on vendor contracts and geographic location.
Future Price Projections (2023–2028)
Factors influencing future pricing:
- Generic/Biosimilar Competition: Entry of biosimilar versions or alternative formulations could cut prices by 20–40% within the next 2–3 years.
- Market penetration and volume growth: Continued expansion in emerging markets and increased PCI procedures support volume growth while exerting pressure on per-unit pricing.
- Regulatory changes: Potential approvals of alternative agents and evolving clinical guidelines could shift demand away from Eptifibatide, impacting pricing.
- Healthcare policy and reimbursement: Enhanced emphasis on value-based care and cost containment measures will influence hospital procurement strategies.
Projected trend:
Based on current competitive forces and market data, the price of NDC 00187-0006 is expected to decline gradually at an average rate of 3–5% annually over the next five years, barring disruptive patent litigations or new therapeutic developments. By 2028, the per-vial price could decrease to approximately $800–$1,000, considering inflation-adjusted market trends and generic adoption rates.
Supply Chain and Distribution Considerations
The supply chain for Eptifibatide involves major pharmaceutical wholesalers, hospital pharmacies, and specialty distributors. Price reductions driven by biosimilar entry could incentivize supply chain consolidation and volume-enhancing strategies. Additionally, pharmaceutical companies may employ discounts and contracting tactics to preserve market share.
Regulatory and Reimbursement Landscape
Reimbursement policies are pivotal in shaping Eptifibatide’s market viability. The Centers for Medicare & Medicaid Services (CMS) and private payers leverage Diagnosis-Related Group (DRG) payments and value-based contracts to influence hospital prescribing habits. Evolving guidelines from the American College of Cardiology (ACC) and American Heart Association (AHA) favor newer agents in some settings, but immediate-use settings like PCI still rely heavily on agents like Eptifibatide.
Conclusion
NDC 00187-0006, representing Eptifibatide, remains an essential component in acute coronary syndrome management. While patent expirations and biosimilar entries exert downward pressure on pricing, volume driven by the global rise in PCI procedures sustains its market presence. The outlook suggests steady but modest price declines aligned with industry trends, with total sales volume expected to grow marginally, especially in emerging markets.
Key Takeaways
- The global PCI and ACS markets underpin the demand for Eptifibatide (NDC 00187-0006), with growth driven by aging populations and lifestyle-related cardiovascular risks.
- Competitive pressure from biosimilars and alternative antiplatelet therapies is shaping a downward trend in drug pricing, averaging 3–5% annually.
- Institutional procurement remains the dominant distribution channel, with hospital and governmental payers influencing pricing strategies.
- Regulatory shifts and evolving clinical guidelines could modulate the drug’s market share, affecting future price trajectories.
- Investors and healthcare providers should monitor biosimilar entry and reimbursement changes, as these are primary determinants of price stability and revenue potential.
FAQs
1. How will biosimilar competition impact the price of Eptifibatide?
Biosimilar entries typically lead to a 20–40% reduction in price within 2–3 years, driven by market competition and demand for cost-effective alternatives.
2. Are there upcoming regulatory changes affecting Eptifibatide?
While no immediate regulatory hurdles are announced, evolving clinical guidelines promoting newer antiplatelet therapies could influence the drug’s clinical and economic desirability.
3. What is the outlook for Eptifibatide’s market share?
The market share is expected to decline gradually in regions favoring oral agents but remains significant in acute hospital settings where intravenous administration is preferred.
4. How do pricing trends vary across geographic markets?
In the U.S., institutional negotiations and reimbursement policies heavily influence pricing, often resulting in lower net prices compared to list prices. Emerging markets may see higher relative market share but with lower absolute prices.
5. What strategic considerations should healthcare providers make?
Providers should balance cost, clinical efficacy, and patient safety when selecting antiplatelet agents. Staying abreast of biosimilar developments and reimbursement policies will optimize procurement strategies.
References
- U.S. Food and Drug Administration. Integrilin (Eptifibatide) Prescribing Information.
- American Heart Association. Heart Disease and Stroke Statistics — 2021.
- Drug Channels Institute. Pharmaceutical Pricing and Market Data.
More… ↓
